This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
April 10, 2012 /PRNewswire/ -- Medizone International, Inc. (MZEI:OB) (MZEI:QB) announced today that the first production unit of its
AsepticSure disinfection technology has been successfully completed by its manufacturing partner, SMTC Corporation (NASDAQ:SMTX).
Following performance confirmation testing of the initial unit, four additional units will immediately be manufactured for independent validation testing and subsequently placed into commercial service. The first five production units are expected to be delivered to Medizone by month's end.
peer reviewed article in the AJIC and more recent
recognition in Geneva for
Innovation Excellence marked the beginning of a series of amazing achievements for Medizone," stated Dr
Michael Shannon, President and Director of Medical Affairs.
"A combination of scientific, developmental and technological advancements made by the company over the past 12 months has seen us arrive at the brink of an exciting new era in Medizone's history.
"I have no doubt whatsoever that AsepticSure is poised to become the gold standard for hospital disinfection," said Shannon.
Medizone International's Chairman and CEO,
Edwin Marshall commented: "In addition to successfully initiating production, we're pleased to announce that
Health Canada recently informed us that they will
not regulate AsepticSure as either a medical device or disinfectant. Additionally, they will
not require a new DIN (drug identification number) for the AsepticSure catalyst.
"The Company views this ruling by Health Canada in the most favorable light. It means that following standard validation testing of the initial production units over the coming 4 weeks, the Company may then begin commercial sales of AsepticSure in Canada.
"For Medizone to successfully develop and launch such a superior, fast-acting (green) disinfection technology capable of
consistently producing 100% bacterial kills on both hard and soft surfaces
withoutleaving any residual residue... it's an amazing achievement. Our R&D, science, regulatory, patent and production teams have done an outstanding job. I couldn't be more proud of them."
In related news, Medizone's regulatory team has also submitted a
Request for Designationin the US, to the FDA.
For press information on Medizone International, please contact: